# US 2025/0375510 A1 · Vaccine for protection against leptospira serovar grippotyphosa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375510 A1
- Document ID: US20250375510A1
- Status: Published application
- Kind: A1
- Application number: 18/873,754
- Filed: 2023-06-21
- Published: 2025-12-11
- Earliest claimed: 2022-06-22
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Henricus Leo Bernardus Maria KLAASEN; Jorrit HEGGE
- Web page: https://patentgrep.com/patent/US20250375510A1

## CPC

- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to providing a canine with protective immunity against Leptospira serovar Grippoty-phosa with a vaccine that comprises a non-Grippotyphosa Leptospira serovar.

## Claims

### Claim 1

A method for inducing an immune response to Leptospira serovar Grippotyphosa in a canine, comprising administering to the canine a vaccine comprising a non-Grippotyphosa Leptospira serovar.

### Claim 2 (depends on 1)

The method of claim 1 wherein the vaccine is a multivalent vaccine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vaccine does not comprise Leptospira serovar Grippotyphosa.

### Claim 4 (depends on 1)

The method of claim 1, wherein the vaccine comprises Leptospira serovars Portland-vere, Dadas, Copenhageni, and/or Bratislava.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises inducing an immune response in the canine against Leptospira serovars Grippotyphosa, Australis, and Icterohaemorrhagiae.

### Claim 6 (depends on 1)

The method of claim 1, wherein 0.1 to 2.5 ml of said vaccine is administered.

### Claim 7 (depends on 1)

The method of claim 1, wherein the vaccine is administered subcutaneously.

### Claim 8 (depends on 1)

The method of claim 1. wherein the vaccine is administered in at least 2 doses.

### Claim 9 (depends on 1)

The method of claim 1, wherein the vaccine is administered in at least 2 doses and the doses are administered at least 5 days apart.

### Claim 10 (depends on 1)

The method of claim 1, wherein the vaccine comprises at least one additional antigen that provides immunity against an additional non-Leptospiral canine pathogen.

### Claim 11 (depends on 10)

The method of claim 10 wherein the additional antigen is selected from the group of: canine parvovirus (CPV), canine parainfluenza virus (CPi2), canine distemper virus (CDV), adenovirus, herpesvirus, rabies, canine coronavirus and combinations thereof. 12 (New) A method of vaccinating a canine against Leptospira serovar Grippotyphosa, comprising administering to the canine a vaccine composition comprising a Leptospira serovar, where the Leptospira serovar is not Grippotyphosa Leptospira.

### Claim 13 (depends on 12)

The method of claim 12, wherein the vaccine is a multivalent vaccine comprising at least two Leptospira serovars, wherein the Leptospira serovars are not Grippotyphosa Leptospira.

### Claim 14 (depends on 13)

The method of claim 13, wherein the vaccine comprises Leptospira serovars Portland-vere, Dadas, Copenhageni, and/or Bratislava.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method further induces an immune response to any one or a combination of: Leptospira serovar Australis, Grippotyphosa, and Icterohaemorrhagiae.

### Claim 16

A method to the reduce risk of infection, or to reduce the severity of one or more clinical sign of infection with Leptospira serovar Grippotyphosa in a canine, or both, comprising administering to the canine a composition comprising a vaccine comprising a Leptospira serovar, where the Leptospira serovar is not Grippotyphosa Leptospira.

### Claim 17 (depends on 16)

The method of claim 16, wherein the vaccine is a multivalent vaccine comprising at least two Leptospira serovars, wherein the Leptospira serovars are not Grippotyphosa Leptospira.

### Claim 18 (depends on 17)

The method of claim 17, wherein the vaccine comprises Leptospira serovars Portland-vere, Dadas, Copenhageni, and/or Bratislava.

### Claim 19 (depends on 18)

The method of claim 18, wherein the method further induces an immune response to any one or a combination of: Leptospira serovar Australis, Grippotyphosa, and Icterohaemorrhagiae.
